Manejo multidisciplinario del cáncer diferenciado de tiroides en el Instituto Nacional de Cancerología

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6.

https://doi.org/10.1002/ijc.1440

Colombia, Ministerio de la Protección Social, Instituto Nacional de Cancerología. Anuario Estadístico 2005. Bogotá: Ministerio de la Protección Social, Instituto Nacional de Cancerología; 2006.

Correa P. Pathology of endemic goiter. En: Stanbury JB (editor). Endemic goiter and endemic cretinism Iodine nutrition in health and disease. New York: John Wiley & Sons; 1980.

Otero E, Martín F. Nódulos tiroideos. Rev Fac Med. 1972;38:66.

Franssila KO, Harach HR. Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland. Cancer. 1986;58(3):715-9.

https://doi.org/10.1002/1097-0142(19860801)58:3<715::AID-CNCR2820580319>3.0.CO;2-P

De Lellis R, Lloyd R, Heitz P, Heng C, editors. Tumours of the thyroid and parathyroid. Lyon: International Agency for Research on Cancer (IARC) Press; 2004.

Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer. 1992;70(6):1585-90.

https://doi.org/10.1002/1097-0142(19920915)70:6<1585::AID-CNCR2820700623>3.0.CO;2-Z

Pacini F, Elisei R, Capezzone M, Miccoli P, Molinaro E, Basolo F, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid. 2001;11(9):877-81.

https://doi.org/10.1089/105072501316973145

Kim ES, Kim TY, Koh JM, Kim YI, Hong SJ, Kim WB, et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol. 2004;61(1):145-8.

https://doi.org/10.1111/j.1365-2265.2004.02065.x

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109-42.

https://doi.org/10.1089/thy.2006.16.109

Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90(10):5723-9.

https://doi.org/10.1210/jc.2005-0285

Soh EY, Clark OH. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am. 1996;25(1):115-39.

https://doi.org/10.1016/S0889-8529(05)70315-7

DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414-24.

https://doi.org/10.1210/jcem-71-2-414

Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134(6):946- 54; discussion 54-5.

https://doi.org/10.1016/S0039-6060(03)00424-0

Watkinson JC, Franklyn JA, Olliff JF. Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid. 2006;16(2):187-94.

https://doi.org/10.1089/thy.2006.16.187

Tollefsen HR, Decosse JJ. Papillary Carcinoma of the Thyroid. Recurrence in the Thyroid Gland after Initial Surgical Treatment. Am J Surg. 1963;106:728-34.

https://doi.org/10.1016/0002-9610(63)90393-3

DeGroot LJ, Kaplan EL. Second operations for "completion" of thyroidectomy in treatment of differentiated thyroid cancer. Surgery. 1991;110(6):936-9; discussion 9-40.

Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97(1):90-6.

https://doi.org/10.1002/cncr.11031

Cadena E, Martínez B. Manejo del cáncer tiroideo invasivo del tracto aerodigestivo alto. Rev Col Cancerol. 2004;8(1):13-20.

Jossart GH, Clark OH. Well-differentiated thyroid cancer. Curr Probl Surg. 1994;31(12):933-1012.

https://doi.org/10.1016/0011-3840(94)90063-9

Friedman M. Surgical management of thyroid carcinoma with laryngotracheal invasion. Otolaryngol Clin North Am. 1990;23(3):495-507.

Musholt TJ, Musholt PB, Behrend M, Raab R, Scheumann GF, Klempnauer J. Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon. Surgery. 1999;126(6):1078-87; discussion 87-8.

https://doi.org/10.1067/msy.2099.102267

Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D (editors). AJCC Cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.

https://doi.org/10.1007/978-1-4757-3656-4

Sherman SI, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, et al. Thyroid Carcinoma [Internet]. Practice Guidelines In Oncology 2008 [citado: 2009 feb]. Disponible en http://www.nccn.org.

Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-63.

https://doi.org/10.1210/jcem.86.4.7407

Garavito G. Factores pronósticos para recaída en pacientes con cáncer papilar de tiroides. Rev Col Cancerol. 2005;9(1):21-30.

Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol. 2007;66(1):58-64.

Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(3):1440-5.

https://doi.org/10.1210/jc.2004-1771

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941-59.

https://doi.org/10.1007/s00259-008-0883-1

Silberstein EB, Alavi A, Balon HR, Becker DV, Brill DR, Clarke SEM, et al. Society of Nuclear Medicine Procedure Guideline for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide). Version 2.0. 2005.

U.S. Nuclear Regulatory Commission. Model procedure for release of patients or human research subjects administered radioactive materials. Rev. 2nd ed; 2008.

do Rosário PW, Fagundes TA, Rezende LL, Padrao EL, Borges MAR, Barroso AL. Assessing hypothyroidism in the preparation of patients with thyroid cancer: cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone and absence from work. . Endocrinologist. 2006;16:25-9.

https://doi.org/10.1097/01.ten.0000194249.60430.2a

Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):619-25.

https://doi.org/10.1210/jcem.86.2.7189

Spencer D. Clinical utility of serum thyroglobulin measurement. Curr Opin Endocrinol Diabetes. 2002;9:401-6.

https://doi.org/10.1097/00060793-200210000-00007

Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91(3):926-32.

https://doi.org/10.1210/jc.2005-1651

Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88(9):4110-5.

https://doi.org/10.1210/jc.2003-030298

Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297-306.

https://doi.org/10.1056/NEJM199801293380506

Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7(3):229-39.

https://doi.org/10.1177/107327480000700302

Guana A. Protocolo de seguimiento en cáncer diferenciado de tiroides. Bogotá: Universidad Nacional de Rosario; 2007.

Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229-42.

https://doi.org/10.1089/thy.2006.16.1229

Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92(7):2610-5.

https://doi.org/10.1210/jc.2006-2566

Spencer C. New insights for using serum thyroglobulin (Tg) measurement for managing patients with differentiated thyroid carcinomas. Thyroid International. 2003;4:1-14.

Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab. 2004;89(8):3702-4.

https://doi.org/10.1210/jc.2004-0986

Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol. 2002;57(2):215-21.

https://doi.org/10.1046/j.1365-2265.2002.01592.x

Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46(7):1079-88.

Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am. 1995;24(4):841-63.

https://doi.org/10.1016/S0889-8529(18)30023-9

Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150(2):105-12.

https://doi.org/10.1530/eje.0.1500105

Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86(9):4092-7.

https://doi.org/10.1210/jcem.86.9.7831

Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88(3):1107-11.

https://doi.org/10.1210/jc.2002-021365

Sutton RT, Reading CC, Charboneau JW, James EM, Grant CS, Hay ID. US-guided biopsy of neck masses in postoperative management of patients with thyroid cancer. Radiology. 1988;168(3):769-72.

https://doi.org/10.1148/radiology.168.3.3043550

Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(4):1433-41.

https://doi.org/10.1210/jc.2002-021702

Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87(7):3242-7.

https://doi.org/10.1210/jcem.87.7.8702

Gor DM, Langer JE, Loevner LA. Imaging of cervical lymph nodes in head and neck cancer: the basics. Radiol Clin North Am. 2006;44(1):101-10, viii.

https://doi.org/10.1016/j.rcl.2005.08.006

do Rosário PW, Fagundes TA, Maia FF, Franco AC, Figueiredo MB, Purisch S. Sonography in the diagnosis of cervical recurrence in patients with differentiated thyroid carcinoma. J Ultrasound Med. 2004;23(7):915-20; quiz 21-2.

https://doi.org/10.7863/jum.2004.23.7.915

Chikui T, Yonetsu K, Nakamura T. Multivariate feature analysis of sonographic findings of metastatic cervical lymph nodes: contribution of blood flow features revealed by power Doppler sonography for predicting metastasis. AJNR Am J Neuroradiol. 2000;21(3):561-7.

Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92(9):3590-4.

https://doi.org/10.1210/jc.2007-0444

Kupferman ME, Patterson DM, Mandel SJ, LiVolsi V, Weber RS. Safety of modified radical neck dissection for differentiated thyroid carcinoma. Laryngoscope. 2004;114(3):403-6.

https://doi.org/10.1097/00005537-200403000-00002

Noguchi S, Yamashita H, Murakami N, Nakayama I, Toda M, Kawamoto H. Small carcinomas of the thyroid. A long-term follow-up of 867 patients. Arch Surg. 1996;131(2):187-91.

https://doi.org/10.1001/archsurg.1996.01430140077021

Marchesi M, Biffoni M, Biancari F, Berni A, Campana FP. Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma. Eur J Surg Suppl. 2003;(588):46-50.

Graham M, Menda Y. Positron emision tomography/com- puted tomography imaging of head and neck tumors: an atlas. Semin Nucl Med. 2005;35(4):220-52.

https://doi.org/10.1053/j.semnuclmed.2005.05.002